T-1301

N/A

Report date: 2025/06/05 16:57:43

NME

Base Information

Drug NameT-1301

Drug Alias NameT-1301DBPR-216BPR-1J481BPR1J481

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionABL proto-oncogene 1 inhibitorsNeurotrophic tyrosine kinase receptor type 2 inhibitorsTyrosine-protein kinase receptor FLT3 inhibitors +[8]

TargetsABL proto-oncogene 1Neurotrophic tyrosine kinase receptor type 2Tyrosine-protein kinase receptor FLT3 +[8]

Therapy Area/IndicationsSolid tumoursLymphoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryTaiwan

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesTaivex Therapeutics Corp

China Registration ClassN/A

Develop Information

Active CompaniesTaivex Therapeutics Corp

Inactive CompaniesN/A

Active IndicationsSolid tumoursLymphoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A